Currently, blinatumomab – an anti-CD3/CD19 BsAb used to treat relapsed ALL (27) – is the only BsAb that is recommended by NICE (Table 1) and is therefore discussed herein. Here, CD19 is linked to acute lymphoblastic leukemia.